166 related articles for article (PubMed ID: 15816793)
41. Clonidine treatment of Gilles de la Tourette's syndrome.
Leckman JF; Hardin MT; Riddle MA; Stevenson J; Ort SI; Cohen DJ
Arch Gen Psychiatry; 1991 Apr; 48(4):324-8. PubMed ID: 2009034
[TBL] [Abstract][Full Text] [Related]
42. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder.
McConville BJ; Sanberg PR; Fogelson MH; King J; Cirino P; Parker KW; Norman AB
Biol Psychiatry; 1992 Apr; 31(8):832-40. PubMed ID: 1643197
[TBL] [Abstract][Full Text] [Related]
43. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study.
Sallee FR; Kurlan R; Goetz CG; Singer H; Scahill L; Law G; Dittman VM; Chappell PB
J Am Acad Child Adolesc Psychiatry; 2000 Mar; 39(3):292-9. PubMed ID: 10714048
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
45. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania.
Van Ameringen M; Mancini C; Patterson B; Bennett M; Oakman J
J Clin Psychiatry; 2010 Oct; 71(10):1336-43. PubMed ID: 20441724
[TBL] [Abstract][Full Text] [Related]
46. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.
Faris PL; Kim SW; Meller WH; Goodale RL; Oakman SA; Hofbauer RD; Marshall AM; Daughters RS; Banerjee-Stevens D; Eckert ED; Hartman BK
Lancet; 2000 Mar; 355(9206):792-7. PubMed ID: 10711927
[TBL] [Abstract][Full Text] [Related]
47. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome.
Shapiro E; Shapiro AK; Fulop G; Hubbard M; Mandeli J; Nordlie J; Phillips RA
Arch Gen Psychiatry; 1989 Aug; 46(8):722-30. PubMed ID: 2665687
[TBL] [Abstract][Full Text] [Related]
48. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder.
Feigin A; Kurlan R; McDermott MP; Beach J; Dimitsopulos T; Brower CA; Chapieski L; Trinidad K; Como P; Jankovic J
Neurology; 1996 Apr; 46(4):965-8. PubMed ID: 8780073
[TBL] [Abstract][Full Text] [Related]
49. Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: a double-blind placebo-controlled study.
Scahill L; Riddle MA; King RA; Hardin MT; Rasmusson A; Makuch RW; Leckman JF
J Child Adolesc Psychopharmacol; 1997; 7(2):75-85. PubMed ID: 9334893
[TBL] [Abstract][Full Text] [Related]
50. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome.
Gaffney GR; Perry PJ; Lund BC; Bever-Stille KA; Arndt S; Kuperman S
J Am Acad Child Adolesc Psychiatry; 2002 Mar; 41(3):330-6. PubMed ID: 11886028
[TBL] [Abstract][Full Text] [Related]
51. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder.
Soltani F; Sayyah M; Feizy F; Malayeri A; Siahpoosh A; Motlagh I
Hum Psychopharmacol; 2010 Aug; 25(6):509-13. PubMed ID: 20737524
[TBL] [Abstract][Full Text] [Related]
52. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study.
Gilbert DL; Murphy TK; Jankovic J; Budman CL; Black KJ; Kurlan RM; Coffman KA; McCracken JT; Juncos J; Grant JE; Chipkin RE
Mov Disord; 2018 Aug; 33(8):1272-1280. PubMed ID: 30192018
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.
Coffey B; Jankovic J; Claassen DO; Jimenez-Shahed J; Gertz BJ; Garofalo EA; Stamler DA; Wieman M; Savola JM; Gordon MF; Alexander JK; Barkay H; Harary E
JAMA Netw Open; 2021 Oct; 4(10):e2129397. PubMed ID: 34661664
[TBL] [Abstract][Full Text] [Related]
54. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial.
Bloch MH; Panza KE; Yaffa A; Alvarenga PG; Jakubovski E; Mulqueen JM; Landeros-Weisenberger A; Leckman JF
J Child Adolesc Psychopharmacol; 2016 May; 26(4):327-34. PubMed ID: 27027204
[TBL] [Abstract][Full Text] [Related]
55. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine.
Singer HS; Brown J; Quaskey S; Rosenberg LA; Mellits ED; Denckla MB
Pediatrics; 1995 Jan; 95(1):74-81. PubMed ID: 7770313
[TBL] [Abstract][Full Text] [Related]
56. The Effectiveness of Aripiprazole for Tics, Social Adjustment, and Parental Stress in Children and Adolescents with Tourette's Disorder.
Wang LJ; Chou WJ; Chou MC; Gau SS
J Child Adolesc Psychopharmacol; 2016 Jun; 26(5):442-8. PubMed ID: 27028456
[TBL] [Abstract][Full Text] [Related]
57. Effective open-label treatment of tourette's disorder with olanzapine.
Stamenkovic M; Schindler SD; Aschauer HN; De Zwaan M; Willinger U; Resinger E; Kasper S
Int Clin Psychopharmacol; 2000 Jan; 15(1):23-8. PubMed ID: 10836282
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of a modified comprehensive behavioral intervention for tics for children and adolescents with tourette's syndrome: A randomized controlled trial.
Chen CW; Wang HS; Chang HJ; Hsueh CW
J Adv Nurs; 2020 Mar; 76(3):903-915. PubMed ID: 31782167
[TBL] [Abstract][Full Text] [Related]
59. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.
Müller C; Pongratz S; Pidlich J; Penner E; Kaider A; Schemper M; Raderer M; Scheithauer W; Ferenci P
Eur J Gastroenterol Hepatol; 1998 Oct; 10(10):865-70. PubMed ID: 9831410
[TBL] [Abstract][Full Text] [Related]
60. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
Johnson BA; Roache JD; Javors MA; DiClemente CC; Cloninger CR; Prihoda TJ; Bordnick PS; Ait-Daoud N; Hensler J
JAMA; 2000 Aug 23-30; 284(8):963-71. PubMed ID: 10944641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
